Last updated: June 2026 · Reviewed June 2026 · Built by the InjectBuddy team
How does the retatrutide calculator work? dose to units in plain steps
To turn a retatrutide dose into syringe units, divide the dose in milligrams by the vial concentration in mg/mL to get the volume in mL, then multiply by 100 for the mark on a U-100 insulin syringe. Retatrutide is an investigational triple agonist (GIP, GLP-1 and glucagon receptors) that is still in trials and is not FDA-approved — there is no established human dose outside a study, so the numbers below are a maths reference only, not a dosing recommendation. This guide explains how the calculation works, walks through a dose-to-units chart, provides seven worked examples, and answers the questions people ask most.
Key takeaways
- units = (dose mg ÷ concentration mg/mL) × 100 on a U-100 syringe.
- Concentration depends entirely on how much bacteriostatic water you add — there is no standard retatrutide vial strength.
- Retatrutide is phase 2/3 only; doses studied ran roughly 1–12 mg weekly in trials, but those are research doses, not approved guidance.
- Run your own numbers in the free retatrutide dose calculator.
What retatrutide is (and why "dose" is unsettled)
Retatrutide (development code LY3437943) is a single peptide that activates three receptors at once: the GIP, GLP-1 and glucagon receptors. The discovery and proof-of-concept pharmacology was published by Coskun and colleagues in Cell Metabolism in 2022, describing balanced glucagon and GLP-1 activity with stronger GIP activity and once-weekly dosing in early human studies. Because it engages glucagon as well, it is sometimes called a "triple G" agonist rather than a GLP-1 drug like semaglutide or a dual agonist like tirzepatide.
The honest caveat: retatrutide has only reached phase 2, with phase 3 trials ongoing, and it is not approved by the FDA or any major regulator. The phase 2 obesity trial reported by Jastreboff in the New England Journal of Medicine (2023) tested weekly doses up to 12 mg over 48 weeks; the phase 2 type 2 diabetes trial reported by Rosenstock in The Lancet (2023) tested a similar range. Those are research doses titrated under trial supervision — there is no consumer label, no standard vial, and no established self-administration schedule. This guide explains only the arithmetic of converting a number you already have into a syringe volume.
How this is calculated
The maths is the same volume-and-ratio arithmetic used for any reconstituted peptide. Three quantities matter: the dose (mg of drug you want), the concentration (mg per mL after you add water), and the volume (mL you draw). They relate by one identity:
volume (mL) = dose (mg) ÷ concentration (mg/mL)
Retatrutide ships as a lyophilised (freeze-dried) powder, so the vial itself has no concentration until you add bacteriostatic water. Concentration is set by you: a 10 mg vial reconstituted with 1 mL is 10 mg/mL, but the same vial with 2 mL is 5 mg/mL. That single choice changes every unit number on the page, which is why copying someone else's "units" without matching their water volume is unsafe.
To read the volume on an insulin syringe, convert mL to U-100 units: a U-100 syringe is marked so that 100 units = 1 mL, meaning units = mL × 100. Combine the two steps and the whole conversion is:
units = (dose mg ÷ concentration mg/mL) × 100
No rounding is applied for you here — if a result lands between marks (say 7.5 units), you read the nearest practical line on your syringe. A 0.3 mL syringe spreads small draws across more visible marks than a 1 mL barrel, which helps when volumes are tiny.
Retatrutide dose to units chart
The table below shows the U-100 unit mark for common research dose points at three concentrations you might create by reconstituting a 10 mg vial with 1 mL (10 mg/mL), 2 mL (5 mg/mL) or 2.5 mL (4 mg/mL). Read it as arithmetic, not advice.
| Dose | 10 mg/mL | 5 mg/mL | 4 mg/mL |
|---|---|---|---|
| 1 mg | 10 units | 20 units | 25 units |
| 2 mg | 20 units | 40 units | 50 units |
| 4 mg | 40 units | 80 units | 100 units |
| 6 mg | 60 units | 120 units* | 150 units* |
| 8 mg | 80 units | 160 units* | 200 units* |
| 12 mg | 120 units* | 240 units* | 300 units* |
*Values above 100 units exceed a standard 1 mL U-100 syringe and would need either a more concentrated mix or more than one draw. The table makes the core lesson visible: at a fixed dose, a more dilute mix means more units; at a fixed concentration, a bigger dose means more units.
The concentration ladder, drawn
Worked examples
Each block below is plain arithmetic you can check by hand. They use the trial dose range purely as reference points — none is a recommendation.
10 mg vial + 1 mL water = 10 mg/mL. Dose 2 mg ÷ 10 mg/mL = 0.2 mL. 0.2 mL × 100 = 20 units.
10 mg vial + 2 mL water = 5 mg/mL. Dose 2 mg ÷ 5 mg/mL = 0.4 mL = 40 units. Doubling the water doubled the units for the same 2 mg.
10 mg vial + 2.5 mL water = 4 mg/mL. Dose 4 mg ÷ 4 mg/mL = 1.0 mL = 100 units, exactly filling a 1 mL U-100 syringe.
5 mg/mL mix. Dose 1 mg ÷ 5 mg/mL = 0.2 mL = 20 units. A 0.3 mL syringe makes this small draw easier to read than a 1 mL barrel.
Dose 6 mg ÷ 5 mg/mL = 1.2 mL = 120 units. That exceeds a 1 mL syringe — you would mix more concentrated or split the draw. At 10 mg/mL the same 6 mg is 0.6 mL = 60 units.
1 mg = 1000 mcg, so 0.5 mg = 500 mcg. At 5 mg/mL (5000 mcg/mL): 500 ÷ 5000 = 0.1 mL = 10 units. Mixing mg with mcg without converting is a classic ten-fold error.
A 10 mg vial holds 10 ÷ 2 = 5 doses of 2 mg. At 4 mg/mL that is 5 draws of 50 units (0.5 mL each), using the full 2.5 mL you reconstituted with.
Common mistakes
The biggest error is treating retatrutide units like a fixed recipe. Because the powder has no built-in concentration, your water volume sets everything — 20 units and 40 units can be the identical 2 mg dose from the identical vial, differing only in how much bacteriostatic water was added. Always pair a unit number with its mg/mL.
The second is unit confusion: mixing milligrams with micrograms drops or adds a factor of 1000, and reading a U-100 mark as if it were "mg" treats a volume line as a dose. The third is ignoring that these are trial doses — escalating quickly toward the 12 mg ceiling seen in studies, outside the slow titration and monitoring those trials used, is not something this maths page endorses.
So, how does the retatrutide calculator work?
The retatrutide calculator works by dividing your dose in mg by your vial concentration in mg/mL to get the draw volume in mL, then multiplying by 100 to give the mark on a U-100 insulin syringe — the full formula is units = (dose mg divided by concentration mg/mL) multiplied by 100. Because retatrutide ships as a powder, you set the concentration yourself when you add bacteriostatic water, which means your water volume is part of the calculation. Plug your own numbers into the free retatrutide dose to units calculator to get the syringe mark instantly.
FAQs
How does the retatrutide calculator work?
How do I convert a retatrutide mg dose into syringe units?
Why does the number of units change when I add more water?
Can I copy someone else's retatrutide unit number?
Is retatrutide approved, and is this page a dosing recommendation?
Run your exact vial size, water volume and dose through the free retatrutide dose to units calculator — it returns the U-100 syringe mark instantly and shows the concentration it used.
Sources
- Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022. PMID: 35985340.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PMID: 37366315.
- Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial. Lancet. 2023. PMID: 37385280.
- Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b trial. Lancet. 2022. PMID: 36354040.
- CDC. Safe Injection Practices to Prevent Transmission of Infections to Patients. CDC injection safety guidance.
This guide is for general educational purposes only and does not constitute medical advice. Retatrutide is an investigational compound that is not approved for human use outside clinical trials; nothing here is a dose recommendation. Always follow a qualified prescriber's specific instructions.